Nepstar- Successful listing of uncertain future.doc

 PAGE \* MERGEFORMAT 13 Nepstar: Successful listing of uncertain future Nothing new under the sun. November 9, 2007, China Nepstar Chain Drugstore Co., Ltd. (China Nepstar Chain Drugstore Ltd.) Landing in New York Stock Exchange, financing 334 million U.S. dollars, the stock code for NPD. As China’s largest drug retail business, Nepstar Chain Drugstore Co., Ltd. (hereinafter referred to as Sea King and stars) became the first home in the New York Stock Exchange-listed pharmaceutical retail enterprises in Mainland China. This ‘first home’ is deeply significant. When the Shenyang Sansei, Tongji Group, Kunming, torch, WuXi PharmaTech and other pharmaceutical companies in the United States when the drug retail business is essentially only the ‘allocation’ share, but now, not only because of the controversial OEM Nepstar practice, but also because of its successful grafting with the capital markets, so that drug retailers ‘terminals is king’ is the slogan of Hande increasingly louder. From EMKT. traditional OTC marketing of pharmaceutical, channels, shops are quietly changing the path, drug retail, pharmaceutical and other commercial channels are in an active or passive to find himself in the position of the industry chain. The Nepstar In a sense, is more like that of the origin coordinate system. The challenge of last resort In 1995, the predecessor of Nepstar Nepstar Pharmaceutical Co., Ltd., Shenzhen set up its name from the ‘universe, the stars’ and ‘spread’ meaning, hoping to position themselves as ‘Health + Professional + convenience’ health pharmacy, blooming all over the country. After more than ten years of development, as at the end of October 2007, its number of shops across the country has reached more than 1790, and this figure has increased as the peak, an average of two days to open a new store. At present, Nepstar outside the dispensary has been in Shenzhen accounted for two-thirds of its overall pharmacy. Industry generally believes that Neps